FDA requires thromboembolism warning on testosterone products

Candace Stuart | | Cardiovascular Business | Vascular & Endovascular

Manufacturers of testosterone products will need to add a general warning about the risk of deep vein thrombosis and pulmonary embolism in their labeling, the FDA ruled. The warning is in addition to labeling that highlights thromboembolism as a possible consequence of polycythemia.

The FDA said it called for the change after receiving postmarket reports of thromboembolism unrelated to polycythemia. The labeling is required for all approved testosterone products. The approved products are indicated in men who have no or little levels of testosterone due to medical conditions such as chemotherapy or genetic conditions.

The new warning is separate from an ongoing investigation of the possible risk of stroke, MI and death in patients taking testosterone products. The agency announced Jan. 31 that it was re-evaluating the safety of testosterone treatments based on studies that found a possible increased risk of cardiovascular events in men taking these medications.

Candace Stuart, Contributor

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."